Danaher Nears $10 Billion Acquisition of Masimo

NodeGuardian · 2026-03-10T04:25:33+00:00

Danaher is nearing a $10 billion acquisition of Masimo, enhancing its position in the medical technology sector. This move follows Danaher's previous $21.4 billion Cytiva purchase, reflecting its commitment to biotechnology despite Masimo's stock decline.

NodeGuardian

2026-03-10 04:25:33

Abstract generation in progress

Danaher (DHR) is reportedly close to acquiring Masimo (MASI) for approximately $10 billion, a move that would significantly bolster Danaher’s position in the medical technology sector. This acquisition, if finalized, would be Danaher’s largest since its $21.4 billion purchase of Cytiva, showcasing its continued investment in biotechnology. Despite a recent decline in Masimo’s stock, this deal is expected to provide Danaher with new growth opportunities given the sustained demand for medical devices.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes